VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Clinical trial NCT03556228 · RECRUITING

Trial details

NCT number: NCT03556228
Sponsor: VM Oncology, LLC
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Head and Neck Carcinoma Adenoid Cystic Carcinoma Lung Cancer Non-Small Cell Lung Cancer Pancreatic Cancer Mesothelioma Esophageal Cancer Any Solid Tumors Progressed After a Prior Immunotherapy Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma HNSCC Salivary Gland Carcinomas Head and Neck Cancers - Salivary Gland

Start date: 2018-06-08
Primary completion: 2027-12-01
Enrollment: 242

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.